{"created":"2025-02-21T03:23:23.892060+00:00","id":2006505,"links":{},"metadata":{"_buckets":{"deposit":"ec673656-8b49-4786-af43-bca93eae8ccf"},"_deposit":{"created_by":41,"id":"2006505","owners":[41],"pid":{"revision_id":0,"type":"depid","value":"2006505"},"status":"published"},"_oai":{"id":"oai:hiroshima.repo.nii.ac.jp:02006505","sets":["1730444907710"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Hatooka, Masahiro","creatorNameLang":"en"}],"familyNames":[{"familyName":"Hatooka","familyNameLang":"en"}],"givenNames":[{"givenName":"Masahiro","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kawaoka, Tomokazu","creatorNameLang":"en"}],"familyNames":[{"familyName":"Kawaoka","familyNameLang":"en"}],"givenNames":[{"givenName":"Tomokazu","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Aikata, Hiroshi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Aikata","familyNameLang":"en"}],"givenNames":[{"givenName":"Hiroshi","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Inagaki, Yuki","creatorNameLang":"en"}],"familyNames":[{"familyName":"Inagaki","familyNameLang":"en"}],"givenNames":[{"givenName":"Yuki","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Morio, Kei","creatorNameLang":"en"}],"familyNames":[{"familyName":"Morio","familyNameLang":"en"}],"givenNames":[{"givenName":"Kei","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nakahara, Takasi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Nakahara","familyNameLang":"en"}],"givenNames":[{"givenName":"Takasi","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Murakami, Eisuke","creatorNameLang":"en"}],"familyNames":[{"familyName":"Murakami","familyNameLang":"en"}],"givenNames":[{"givenName":"Eisuke","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tsuge, Masataka","creatorNameLang":"en"}],"familyNames":[{"familyName":"Tsuge","familyNameLang":"en"}],"givenNames":[{"givenName":"Masataka","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hiramatsu, Akira","creatorNameLang":"en"}],"familyNames":[{"familyName":"Hiramatsu","familyNameLang":"en"}],"givenNames":[{"givenName":"Akira","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Imamura, Michio","creatorNameLang":"en"}],"familyNames":[{"familyName":"Imamura","familyNameLang":"en"}],"givenNames":[{"givenName":"Michio","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":", 由育","creatorNameLang":"ja"},{"creatorName":"Kawakami, Yoshiiku","creatorNameLang":"en"}],"familyNames":[{"familyNameLang":"ja"},{"familyName":"Kawakami","familyNameLang":"en"}],"givenNames":[{"givenName":"由育","givenNameLang":"ja"},{"givenName":"Yoshiiku","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Awai, Kazuo","creatorNameLang":"en"}],"familyNames":[{"familyName":"Awai","familyNameLang":"en"}],"givenNames":[{"givenName":"Kazuo","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Masaki, Keiichi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Masaki","familyNameLang":"en"}],"givenNames":[{"givenName":"Keiichi","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Waki, Koji","creatorNameLang":"en"}],"familyNames":[{"familyName":"Waki","familyNameLang":"en"}],"givenNames":[{"givenName":"Koji","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kohno, Hirotaka","creatorNameLang":"en"}],"familyNames":[{"familyName":"Kohno","familyNameLang":"en"}],"givenNames":[{"givenName":"Hirotaka","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kohno, Hiroshi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Kohno","familyNameLang":"en"}],"givenNames":[{"givenName":"Hiroshi","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Moriya, Takashi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Moriya","familyNameLang":"en"}],"givenNames":[{"givenName":"Takashi","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nagaoki, Yuko","creatorNameLang":"en"}],"familyNames":[{"familyName":"Nagaoki","familyNameLang":"en"}],"givenNames":[{"givenName":"Yuko","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tamura, Toru","creatorNameLang":"en"}],"familyNames":[{"familyName":"Tamura","familyNameLang":"en"}],"givenNames":[{"givenName":"Toru","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Amano, Hajime","creatorNameLang":"en"}],"familyNames":[{"familyName":"Amano","familyNameLang":"en"}],"givenNames":[{"givenName":"Hajime","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Katamura, Yoshio","creatorNameLang":"en"}],"familyNames":[{"familyName":"Katamura","familyNameLang":"en"}],"givenNames":[{"givenName":"Yoshio","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Chayama, Kazuaki","creatorNameLang":"en"}],"familyNames":[{"familyName":"Chayama","familyNameLang":"en"}],"givenNames":[{"givenName":"Kazuaki","givenNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated."}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"HAIC","subitem_subject_scheme":"Other"},{"subitem_subject":"HCC","subitem_subject_scheme":"Other"},{"subitem_subject":"RECIST","subitem_subject_scheme":"Other"},{"subitem_subject":"Sorafenib","subitem_subject_scheme":"Other"},{"subitem_subject":"Tumor marker","subitem_subject_scheme":"Other"},{"subitem_subject":"490","subitem_subject_scheme":"NDC"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"[BACKGROUND]:In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative phase II study to assess survival with HAIC or HAIC converted to sorafenib.  [METHODS]:Fifty-five patients were prospectively enrolled. Patients received HAIC as a second course if they had complete response, partial response, or stable disease (SD) with an alpha fetoprotein (AFP) ratio < 1 or a des-γ-carboxy prothrombin (DCP) ratio < 1. Patients were switched to sorafenib if they had SD with an AFP ratio > 1 and a DCP ratio > 1 or disease progression. The primary endpoint was the 1-year survival rate. Secondary endpoints were the 2-year survival rate, HAIC response, survival rate among HAIC responders, progression-free survival, and adverse events.  [RESULTS]:Of the 55 patients in the intent-to-treat population, the 1-year and 2-year survival rates were 64.0 and 48.3%, respectively. After the first course of HAIC, one (1.8%) patient showed complete response, 13 (23.6%) showed partial response, 30 (54.5%) had SD, and 10 (18.1%) patients had progressive disease. Twenty-three patients (41.8%) had SD with AFP ratios < 1 or DCP ratios < 1, and 7 (12.7%) had SD with AFP ratios > 1 and DCP ratios > 1. Thirty-seven patients (68.5%) were responders and 17 (30.9%) were non-responders to HAIC. In responders, the 1-year and 2-year survival rates were 78 and 62%, respectively.  [CONCLUSION]:Given the results of this study, this protocol deserves consideration for patients with advanced HCC. This trial was registered prospectively from December 12. 2012 to September 1. 2016.","subitem_description_language":"en"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"BioMed Central"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"1471-2407","subitem_source_identifier_type":"ISSN"}]},"item_1617187024783":{"attribute_name":"Page Start","attribute_value_mlt":[{"subitem_start_page":"633"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-06-04","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"633","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"BMC Cancer"},{"bibliographic_title":"BMC Cancer"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1186/s12885-018-4519-y","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1186/s12885-018-4519-y","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"29866075","subitem_relation_type_select":"PMID"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-03-18"}],"displaytype":"simple","filename":"bmcc_18_633.pdf","filesize":[{"value":"1.0 MB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2006505/files/bmcc_18_633.pdf"},"version_id":"afdfe507-5e5c-4101-8055-cd05b0a4bbd5"}]},"item_1732771732025":{"attribute_name":"旧ID","attribute_value":"47069"},"item_title":"Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial","item_type_id":"40003","owner":"41","path":["1730444907710"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-03-18"},"publish_date":"2023-03-18","publish_status":"0","recid":"2006505","relation_version_is_last":true,"title":["Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial"],"weko_creator_id":"41","weko_shared_id":-1},"updated":"2025-02-21T07:44:26.076650+00:00"}